Multiplicity adjustment for multiple endpoints in clinical trials with multiple doses of an active treatment

被引:15
|
作者
Quan, H [1 ]
Luo, XH [1 ]
Capizzi, T [1 ]
机构
[1] Merck & Co Inc, Res Labs, Clin Biostat & Res Decis Sci, Rahway, NJ 07065 USA
关键词
closed procedure; family-wise error rate; strong control; weak control; adjusted p-value;
D O I
10.1002/sim.2101
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Frequently, multiple doses of an active treatment and multiple endpoints are simultaneously considered in the designs of clinical trials. For these trials, traditional multiplicity adjustment procedures such as Bonferroni, Hochberg and Hommel procedures can be applied when treating the comparisons of different doses to the control on all endpoints at the same level. However, these approaches will not take into account the possible dose-response relationship on each endpoint, and therefore are less specific and may have lower power. To gain power, in this paper, we consider the problem as a two-dimensional multiplicity problem: one dimension concerns the multiple doses and the other dimension concerns the multiple endpoints. We propose procedures which consider the dose order to form the closure of the procedures and control the family-wise type I error rate in a strong sense. For this two-dimensional problem, numerical examples show that procedures proposed in this paper in general have higher power than the commonly used procedures (e.g. the regular Hochberg procedure) especially for comparing the higher dose to the control. Copyright (c) 2005 John Wiley & Sons, Ltd.
引用
收藏
页码:2151 / 2170
页数:20
相关论文
共 50 条
  • [1] Multiplicity Adjustment for Clinical Trials With Two Doses of an Active Treatment and Multiple Primary and Secondary Endpoints
    Quan, Hui
    Capizzi, Thomas
    Zhang, Ji
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2009, 1 (03): : 258 - 267
  • [2] Some Multiplicity Adjustment Procedures for Clinical Trials with Sequential Design and Multiple Endpoints
    Luo, Xiaodong
    Quan, Hui
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2024, 16 (01): : 104 - 115
  • [3] Multiplicity Adjustment and Sample Size Calculation in Clinical Trials with Multiple Endpoints: An Industry Survey of Current Practices in Japan
    Kentaro Sakamaki
    Yusuke Morita
    Katsuhiro Iba
    Toshifumi Kamiura
    Seitaro Yoshida
    Naoyuki Ogawa
    Hideki Suganami
    Satoru Tsuchiya
    Satoru Fukimbara
    Therapeutic Innovation & Regulatory Science, 2020, 54 : 1097 - 1105
  • [4] Multiplicity Adjustment and Sample Size Calculation in Clinical Trials with Multiple Endpoints: An Industry Survey of Current Practices in Japan
    Sakamaki, Kentaro
    Morita, Yusuke
    Iba, Katsuhiro
    Kamiura, Toshifumi
    Yoshida, Seitaro
    Ogawa, Naoyuki
    Suganami, Hideki
    Tsuchiya, Satoru
    Fukimbara, Satoru
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (05) : 1097 - 1105
  • [5] Statistical planning in confirmatory clinical trials with multiple treatment groups, multiple visits, and multiple endpoints
    Sun, Hengrui
    Snyder, Ellen
    Koch, Gary G.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2018, 28 (01) : 189 - 211
  • [6] How to deal with multiple endpoints in clinical trials
    Neuhaeuser, Markus
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2006, 20 (06) : 515 - 523
  • [7] Multiplicity Issues in Clinical Trials With Multiple Objectives
    Huque, Mohammad F.
    Dmitrienko, Alex
    D'Agostino, Ralph
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2013, 5 (04): : 321 - 337
  • [8] Multistage nonparametric tests for treatment comparisons in clinical trials with multiple primary endpoints
    Huang, Peng
    Tan, Ming T.
    STATISTICS AND ITS INTERFACE, 2016, 9 (03) : 343 - 354
  • [9] Procedures for testing multiple endpoints in clinical trials: An overview
    Wassmer, G
    Reitmeir, P
    Kieser, M
    Lehmacher, W
    JOURNAL OF STATISTICAL PLANNING AND INFERENCE, 1999, 82 (1-2) : 69 - 81
  • [10] Implementing optimal allocation in clinical trials with multiple endpoints
    Wang, Lu
    Chen, Yong
    Zhu, Hongjian
    JOURNAL OF STATISTICAL PLANNING AND INFERENCE, 2017, 182 : 88 - 99